Tag: Sirtex Medical
Versatility meets control with SIR-Spheres personalised Y90 radioembolization
When performing liver-directed therapy, precise targeting of tumours is crucial to protect healthy liver tissue. Supporting a tailored and flexible approach to radioembolization, SIR-Spheres...
Sirtex Medical granted EU medical device regulation for Y90 resin micospheres
Sirtex Medical has today announced that it has received certification according to European medical device regulation (MDR) 2017/745 for SIR-Spheres Y90 resin microspheres and...
Multidisciplinary panel supports the positive role of SIRT at SUMM90YT conference
This advertorial is sponsored by Sirtex Medical, is only available in selected countries and geographies.
The SUMM90YT conference (23 February, Frankfurt, Germany)—hosted by Sirtex—gathered leading...
Sirtex Medical appoints Matt Schmidt as new chief executive officer
Sirtex Medical, a manufacturer of interventional treatment solutions, announced today the appointment of Matt Schmidt as chief executive officer and board of directors member,...
Sirtex Medical and Grand Pharmaceutical Group Limited granted NDA approval of...
Sirtex Medical has announced with Grand Pharmaceutical Group Limited, that SIR-Spheres Y-90 resin microspheres have been approved by the national medical products administration (NMPA)...
How SIR-Spheres® Y-90 resin microspheres can improve patient outcomes, offer greater...
This advertorial is sponsored by Sirtex Medical.
Two experts in the field of interventional radiology, Bernhard Gebauer (head of interventional radiology at Charité – Universitätsmedizin...
Sirtex Medical and China Grand Pharmaceutical announce successful first administration of...
Sirtex Medical (Sirtex) has announced that the first procedure of selective internal radiation therapy (SIRT) using SIRSpheres Y-90 resin microspheres in China was successfully...
Sirtex Medical announces strategic investment in BlackSwan Vascular
Sirtex Medical (Sirtex) has announced a strategic investment in BlackSwan Vascular (BlackSwan), a private company developing therapies in endovascular embolization. The investment provides resources...
Sirtex Medical completes enrollment of landmark US RESiN registry
Sirtex Medical reports that enrollment in the US RESiN registry has reached a milestone of 1,650 patients and 12.8 months of follow-up, allowing for...
